Cereno Scientific says Phase IIb EPIMODE trial of CS1 in pulmonary arterial hypertension begins screening patients
Reuters2026/09/08 05:48- Cereno Scientific flagged progress in two pulmonary hypertension programs as it prepared for investor meetings at Nordic Life Science Days.
- CS1’s global Phase IIb EPIMODE trial in pulmonary arterial hypertension is screening patients; results have not been presented.
- CS014 topline results from an FDA-aligned Phase I pharmacokinetic bridging study are expected in Q3 2026; results will be presented later.
- Positive CS014 readout could support a streamlined move into Phase IIb in PH-ILD, with trial initiation planned for Q3 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Dogecoin ETF Closure Sets October Exit for Bitwise BWOW Holders
Crypto prices
More
